Now more than ever, international cooperation is needed to fight back against the pandemic. A protectionist approach to R&D will serve no one’s interests
Early stage human trials for vaccine against the virus are ‘days or weeks’ away, but it will take at least 12 – 18 months to complete safety and efficacy tests, and much more money is needed
Vaccines could offer hope - but who to vaccinate, and against what, has no clear answer yet. Read IMI Executive Director Dr Pierre Meulien’s perspective on what is needed to tackle antimicrobial resistance.
Vaccines are an effective public health measure, yet public distrust in immunisation is resulting in outbreaks of preventable diseases. IMI’s ADVANCE project worked to create an open system for monitoring vaccine coverage, benefits and risks in Europe.
Experts decry record-breaking scepticism towards vaccines across the EU and plead with member states to monitor attitudes and work to build public confidence
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.